Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2012. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the GlaxoSmithKline Annual Investment Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details an increase in shareholdings for a specific director through dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports on compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Director Transaction: Dr. M M Slaoui increased his interest in Ordinary Shares via the Annual Investment Plan.
- Transaction Dates and Volume: 439 shares were acquired on April 19, 2012, and 284 shares on July 9, 2012.
- Share Prices: Dividends were reinvested at 1458 pence per share (April 12) and 1495 pence per share (July 5).
- Reporting Nature: This filing does not contain financial results or strategic updates.